Limits...
A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome.

Pinto-Bonilla JC, Del Olmo-Jimeno A, Llovet-Osuna F, Hernández-Galilea E - Ther Clin Risk Manag (2015)

Bottom Line: Patient satisfaction improved from 44.5±19.0 to 70.2±19.2 mm during Thealoz Duo(®) treatment and from 47.2±23 to 57.1±19.1 mm during Systane(®) treatment (P=0.043, mixed-effects analysis of covariance).There were no statistically significant advantages for Systane(®) over Thealoz Duo(®) for any measured parameter.No adverse events were reported.

View Article: PubMed Central - PubMed

Affiliation: Department of Corneal, Refractive, and Cataract Surgery, European Ophthalmological Institute, Clínica Baviera, Pamplona, Navarra, Spain.

ABSTRACT
Dry eye is a common disorder in routine ophthalmological practice, and a better understanding of the complex pathophysiology is leading to improved treatment. Thealoz Duo(®) is a novel artificial tear preparation containing two active ingredients: Trehalose, a naturally occurring disaccharide with anhydrobiotic functions in many organisms, and hyaluronate, a widely distributed anionic glycosaminoglycan polysaccharide with lubricative and water-retaining properties in biological systems. In a randomized, single center, open label, crossover study, 17 adult patients with moderate-to-severe dry eye syndrome were randomized to treatment with Thealoz Duo(®) (combining trehalose and hyaluronic acid) or Systane(®). Patients received 7 days of treatment. The primary efficacy variable was patient satisfaction evaluated by a 0-100 visual analog scale evaluated on days 0 and 7 of treatment. Secondary parameters included ocular surface disease index (OSDI), symptoms of dry eye, ocular staining scores (fluorescein and lissamine green), ocular clinical signs, Schirmer test, tear breakup time, and global efficacy assessed by the patient and the investigator. Seventeen patients were included. Patient satisfaction improved from 44.5±19.0 to 70.2±19.2 mm during Thealoz Duo(®) treatment and from 47.2±23 to 57.1±19.1 mm during Systane(®) treatment (P=0.043, mixed-effects analysis of covariance). Two secondary efficacy parameters (dry eye symptoms and the impact of their symptoms on work) showed statistically significant advantages for Thealoz Duo(®) over Systane(®). There were no statistically significant advantages for Systane(®) over Thealoz Duo(®) for any measured parameter. No adverse events were reported. Thealoz Duo(®) appears to be an effective combination of two active ingredients for the treatment of dry eye and is at least as effective as Systane(®).

No MeSH data available.


Related in: MedlinePlus

OSDI scores at baseline and during treatment at baseline and after 7 days’ treatment with Thealoz Duo® or Systane®.Note: Values represented are mean ± SD.Abbreviation: OSDI, ocular surface disease index.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4403513&req=5

f1-tcrm-11-595: OSDI scores at baseline and during treatment at baseline and after 7 days’ treatment with Thealoz Duo® or Systane®.Note: Values represented are mean ± SD.Abbreviation: OSDI, ocular surface disease index.

Mentions: OSDI fell during treatment with both Thealoz Duo® and Systane® (Figure 1). The reduction in OSDI was 15.2±10.9 for Thealoz Duo® and 9.0±11.9 for Systane®. The difference between the treatments was not statistically significant (P=0.22).


A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome.

Pinto-Bonilla JC, Del Olmo-Jimeno A, Llovet-Osuna F, Hernández-Galilea E - Ther Clin Risk Manag (2015)

OSDI scores at baseline and during treatment at baseline and after 7 days’ treatment with Thealoz Duo® or Systane®.Note: Values represented are mean ± SD.Abbreviation: OSDI, ocular surface disease index.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4403513&req=5

f1-tcrm-11-595: OSDI scores at baseline and during treatment at baseline and after 7 days’ treatment with Thealoz Duo® or Systane®.Note: Values represented are mean ± SD.Abbreviation: OSDI, ocular surface disease index.
Mentions: OSDI fell during treatment with both Thealoz Duo® and Systane® (Figure 1). The reduction in OSDI was 15.2±10.9 for Thealoz Duo® and 9.0±11.9 for Systane®. The difference between the treatments was not statistically significant (P=0.22).

Bottom Line: Patient satisfaction improved from 44.5±19.0 to 70.2±19.2 mm during Thealoz Duo(®) treatment and from 47.2±23 to 57.1±19.1 mm during Systane(®) treatment (P=0.043, mixed-effects analysis of covariance).There were no statistically significant advantages for Systane(®) over Thealoz Duo(®) for any measured parameter.No adverse events were reported.

View Article: PubMed Central - PubMed

Affiliation: Department of Corneal, Refractive, and Cataract Surgery, European Ophthalmological Institute, Clínica Baviera, Pamplona, Navarra, Spain.

ABSTRACT
Dry eye is a common disorder in routine ophthalmological practice, and a better understanding of the complex pathophysiology is leading to improved treatment. Thealoz Duo(®) is a novel artificial tear preparation containing two active ingredients: Trehalose, a naturally occurring disaccharide with anhydrobiotic functions in many organisms, and hyaluronate, a widely distributed anionic glycosaminoglycan polysaccharide with lubricative and water-retaining properties in biological systems. In a randomized, single center, open label, crossover study, 17 adult patients with moderate-to-severe dry eye syndrome were randomized to treatment with Thealoz Duo(®) (combining trehalose and hyaluronic acid) or Systane(®). Patients received 7 days of treatment. The primary efficacy variable was patient satisfaction evaluated by a 0-100 visual analog scale evaluated on days 0 and 7 of treatment. Secondary parameters included ocular surface disease index (OSDI), symptoms of dry eye, ocular staining scores (fluorescein and lissamine green), ocular clinical signs, Schirmer test, tear breakup time, and global efficacy assessed by the patient and the investigator. Seventeen patients were included. Patient satisfaction improved from 44.5±19.0 to 70.2±19.2 mm during Thealoz Duo(®) treatment and from 47.2±23 to 57.1±19.1 mm during Systane(®) treatment (P=0.043, mixed-effects analysis of covariance). Two secondary efficacy parameters (dry eye symptoms and the impact of their symptoms on work) showed statistically significant advantages for Thealoz Duo(®) over Systane(®). There were no statistically significant advantages for Systane(®) over Thealoz Duo(®) for any measured parameter. No adverse events were reported. Thealoz Duo(®) appears to be an effective combination of two active ingredients for the treatment of dry eye and is at least as effective as Systane(®).

No MeSH data available.


Related in: MedlinePlus